Chemically Defined hPSC Culture for Mature Skeletal Muscle Progenitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protocols for generating skeletal muscle progenitor cells (SMPCs) from human pluripotent stem cells (hPSCs) are inadequate, resulting in heterogeneous and functionally immature cells, which limits their clinical utility for muscle diseases.
Innovation Solution
A method involving a specific culture regimen using chemically defined media with growth factors and inhibitors, followed by enrichment and sorting techniques to generate and expand PAX7+ SMPCs, enhancing their myogenic potential and engraftment capability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral-mediated overexpression of transcription factors (MYOD or PAX7) is used to generate skeletal muscle from hPSCs, then skeletal muscle cells can be produced, but the cells are heterogeneous and functionally immature
Solution Approach 1:
The patent extracts and removes the viral-mediated overexpression step from the differentiation protocol. Instead of using viral transduction to force expression of MYOD or PAX7, the invention uses a refined culture regimen with chemically defined media and growth factors that naturally guide hPSCs through developmental stages to produce homogeneous, functional SMPCs without viral intervention.
Solution Approach 2:
The patent changes the parameters of the culture system by using chemically defined media with specific growth factors (BMP4, FGF2, IGF-1) and inhibitors (SB431542, LDN-193189) at controlled concentrations and time points. This parameter optimization enables precise control over differentiation timing and cell fate decisions, producing uniform, functional SMPCs without viral transduction.
2Productivity
If existing protocols are used to generate skeletal muscle progenitor cells, then some cells can be obtained, but insufficient quantity and quality are produced for clinical engraftment
Solution Approach 1:
The patent applies preliminary actions by first generating a large pool of intermediate progenitor cells (expressing Pax3, Pax7, Myf5) before final myogenic differentiation. The optimized culture regimen includes preliminary steps with BMP4 and FGF2 to expand the progenitor pool, followed by controlled differentiation to produce sufficient numbers of functional SMPCs ready for clinical engraftment.
Solution Approach 2:
The patent maintains continuity of useful action through a seamless, multi-stage differentiation protocol without interruptions or viral transduction steps. The chemically defined media regimen continuously guides cells through specification, proliferation, and differentiation phases, ensuring both high yield and clinical-grade quality of SMPCs throughout the process.
3Adaptability or versatility
If hPSCs are differentiated to specific lineages for cell therapies, then cells can be produced for disease treatment, but the cells are functionally immature compared to physiologically relevant cells
Solution Approach 1:
The patent applies dynamics by using time-dependent addition and removal of growth factors and inhibitors during differentiation. The culture regimen dynamically adjusts conditions: BMP4 and FGF2 are added at specific times to drive progenitor expansion, while SB431542 and LDN-193189 are used temporarily to block inhibitory pathways, then removed to allow terminal differentiation. This dynamic control produces functionally mature SMPCs suitable for therapy.
Data Source
Figure 1A
Figure 1A
Figure 1B
AI summary
The present disclosure provides methods of generating skeletal muscle progenitor cells (SMPCs). The present disclosure provides methods of generating immature SMPCs and multinucleated muscle cells, and matured SMPCs and multinucleated muscle cells. The present disclosure provides engraftment methods and treatment methods, involving generating SMPCs and introducing the SMPCs into an individual.